FDMT(FDMT)
FDMT
11/21/26
4D Molecular Therapeutics (FDMT)
Saturday
10:46 PM ET
ThesisRecent positive clinical trial results and strategic partnerships are enhancing investor confidence in the company's growth potential.
Revenue Outlook
What’s Driving the Stock
- 01Recent clinical trial results for lead candidate show a 75% improvement in patient outcomes compared to standard therapies.
- 02New partnership with a major pharmaceutical company expected to provide $50 million in upfront payments and milestone incentives.
- 03FDA fast track designation received for a new gene therapy targeting a rare genetic disorder.
- 04Increased investor interest in gene therapies as evidenced by a 30% increase in sector ETF inflows.
- 05Growing demand for targeted gene therapies
- 06Increased investment in biotechnology innovation
- 07Progress in clinical trials for lead gene therapy candidates, particularly for rare diseases
- 08Partnership announcements or expansions with major pharmaceutical companies
FY2025 Snapshot
- Revenue
- $85M
- Rev. Growth
- +230195%
- Gross Margin
- 91.1%
- Op. Margin
- -187%
- Net Margin
- -164%
- Net Income
- $-140M
- NI Growth
- +12.9%
- EPS
- $-2.42
- 1Y Return
- -5.3%
FDMT Chart
My Notes
- "Our advancements in gene therapy are setting new standards in treatment efficacy."
- Moat: The proprietary AAV platform provides a significant barrier to entry, but ongoing innovation is critical to maintain this advantage.
- growth - Investors looking for high-risk, high-reward opportunities in the biotech space.
- Moderate - Rising interest rates could increase the cost of capital for R&D funding, potentially impacting growth plans and valuations.
- Watch on earnings: Clinical trial success rates, Partnership revenue growth, Cash runway (months until funding is needed).
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $14M to $18M as recent clinical trial results for lead candidate show a 75% improvement in patient outcomes compared to standard.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
Explore More
FDMT Financial Metrics
Explore 130+ historical metrics & ratios
Stock Comparison
Compare equities side by side
52-Week Highs Breakout
Stocks breaking to new annual highs
52-Week Lows Oversold
S&P 500 oversold value screener
Trending Momentum
Relative strength momentum leaders
Earnings Calendar
Upcoming earnings dates & reports
S&P 500 Screener
Filter and sort all 500 stocks
Market Movers
Today's biggest gainers and losers
Market Heatmap
Visual sector performance